Glaxosmithkline Share News (GSK)

Malaria drug may help in cancer fight, early research finds

LONDON, July 25 (Reuters) - An off-patent malaria drug could help to destroy cancer cells by making them more susceptible to radiotherapy, according to early work that has prompted British scientists to start a clinical trial. Researchers reported on Monday that atovaquone boosted oxygen le

UK Earnings, Trading Statements Calendar - Next 7 Days

Your inhaler's watching you: drugmakers race for smart devices

* Digitally connected devices aim to track medicine use * GSK, AstraZeneca, Novartis all working on smart inhalers * Innovation drive comes as sector faces growing competition By Ben Hirschler LONDON, July 20 (Reuters) - Makers of inhalers to treat asthma and chronic lung

Novartis in no rush to sell down stake on GSK consumer venture

July 19 (Reuters) - Novartis is happy with the performance of its consumer health joint venture with GlaxoSmithKline, in which the Swiss drugmaker has a minority stake, and is in no rush to exit the collaboration early, its chief executive said. There has been speculation that Novartis migh

Apple teams up with GlaxoSmithKline for ResearchKit project

(ShareCast News) - Apple has stepped up its foray into the health technology world, teaming up with British firm GlaxoSmithKline for a project using ResearchKit, a medical platform for studies and clinical trials. The two companies will gather data from patients using an iOS app powered by ResearchK

Capita bumps up forecast for 2016 dividends, mid-caps to take Brexit hit

(ShareCast News) - The fall in sterling following Brexit would deliver an immediate boost to the value of companies' dividend payments but potential recessionary pressures would hit profits and dividends from UK-focused mid-caps hardest, Capita said in its second quarter 2016 Dividend Monitor. De

Glaxo's ViiV Sees Positive Results In Phase IIIb Triumeq Study

Glaxo Gets China Approval For Cervarix Cervical Cancer Vaccine

Broker tips: GSK, Sage, Burberry

(ShareCast News) - Shares in GlaxoSmithKline rose on Thursday as Jefferies upgraded the stock to 'buy' from 'hold' and lifted the target price to 2,000p from 1,650p. "We have upgraded GSK to 'buy' from 'hold' with a target price of 2,000p as we believe that the improving yield quality will continue

BUZZ-GSK dividend looks safe post-Brexit, even with new CEO

** Jefferies analysts upgrade GlaxoSmithKline to buy from hold with 2,000p PT on growing confidence in drugmaker's 4.9% dividend yield. Stock up 1.5% at 1,670p ** Say fears of a dividend cut linked to the appointment of a new CEO are "overdone" and estimate 2015 payout ratio of 132% will fa

BROKER RATINGS SUMMARY: Goldman Sachs Cuts ASOS To Neutral From Buy

LONDON BRIEFING: Focus On Both Downing Street And Threadneedle Street

BROKER RATINGS SUMMARY: Vodafone Cut To Neutral, ITV Raised To Neutral

Pound weakness to boost Glaxo´s second quarter sales and EPS

(ShareCast News) - The pound´s depreciation against the US dollar and Japanese yen during the second quarter of the year were set to significantly boost GlaxoSmithKline´s reported sales and profits in sterling terms, the company said. During the quarter ended on 30 June 2016 the pound had traded at

BROKER RATINGS SUMMARY: Property Stocks Continue To Receive Downgrades